Nuveen LLC Invests $4.39 Million in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Nuveen LLC acquired 134,127 shares of Supernus Pharmaceuticals, valued at approximately $4.39 million, marking a new stake in the company during the first quarter.
• Insider trading activity included notable sales, with Director Bethany Sensenig and CFO Timothy C. Dec selling shares valued at over $750,000 in total, resulting in a significant decrease in their holdings.
• Recent analyst activity saw upgrades for Supernus Pharmaceuticals, with Wall Street Zen changing its rating from "hold" to "buy" and Cantor Fitzgerald raising the target price from $42 to $46.

Nuveen LLC purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 134,127 shares of the specialty pharmaceutical company's stock, valued at approximately $4,393,000. Nuveen LLC owned 0.24% of Supernus Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Invesco Ltd. raised its holdings in Supernus Pharmaceuticals by 4.4% during the first quarter. Invesco Ltd. now owns 530,631 shares of the specialty pharmaceutical company's stock worth $17,378,000 after purchasing an additional 22,562 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Supernus Pharmaceuticals by 4.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 16,097 shares of the specialty pharmaceutical company's stock valued at $527,000 after purchasing an additional 726 shares during the period. Commerce Bank raised its stake in shares of Supernus Pharmaceuticals by 12.9% in the 1st quarter. Commerce Bank now owns 15,025 shares of the specialty pharmaceutical company's stock worth $492,000 after buying an additional 1,720 shares in the last quarter. Jefferies Financial Group Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 230.5% in the first quarter. Jefferies Financial Group Inc. now owns 81,313 shares of the specialty pharmaceutical company's stock valued at $2,663,000 after buying an additional 56,713 shares during the period. Finally, Natixis Advisors LLC lifted its holdings in shares of Supernus Pharmaceuticals by 3.4% in the first quarter. Natixis Advisors LLC now owns 40,391 shares of the specialty pharmaceutical company's stock valued at $1,323,000 after buying an additional 1,324 shares during the period.

Wall Street Analyst Weigh In

SUPN has been the topic of several research reports. Cantor Fitzgerald boosted their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Piper Sandler increased their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research note on Friday. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $43.00.

Supernus Pharmaceuticals Trading Down 0.6%

SUPN stock traded down $0.25 during mid-day trading on Monday, reaching $45.12. 481,773 shares of the stock traded hands, compared to its average volume of 993,234. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $45.60. The stock's fifty day moving average is $36.89 and its 200-day moving average is $33.91. The company has a market cap of $2.53 billion, a P/E ratio of 39.23 and a beta of 0.79.

Insiders Place Their Bets

In other news, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $42.26, for a total value of $315,132.82. Following the completion of the sale, the director owned 46,307 shares in the company, valued at $1,956,933.82. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Frank Mottola sold 14,000 shares of Supernus Pharmaceuticals stock in a transaction on Monday, August 25th. The shares were sold at an average price of $44.51, for a total value of $623,140.00. Following the transaction, the senior vice president owned 15,496 shares in the company, valued at $689,726.96. This represents a 47.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 179,606 shares of company stock worth $7,617,005 in the last quarter. Corporate insiders own 8.80% of the company's stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.